AU2021328673A1 - CRF2 receptor agonists and their use in therapy - Google Patents

CRF2 receptor agonists and their use in therapy Download PDF

Info

Publication number
AU2021328673A1
AU2021328673A1 AU2021328673A AU2021328673A AU2021328673A1 AU 2021328673 A1 AU2021328673 A1 AU 2021328673A1 AU 2021328673 A AU2021328673 A AU 2021328673A AU 2021328673 A AU2021328673 A AU 2021328673A AU 2021328673 A1 AU2021328673 A1 AU 2021328673A1
Authority
AU
Australia
Prior art keywords
lysine
glutamine
gglu
glutamate
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021328673A
Other languages
English (en)
Inventor
Philippe Beauverger
Elisabetta Bianchi
Ralf Elvert
Andreas Evers
Nis Halland
Stephane Illiano
Philip Janiak
Laetitia LEDEIN
Ziyu Li
Laurence LUCATS
Marie-Laure OUZOUX
Daniela ROVERSI
Alessia Santoprete
Martina TRIPEPI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of AU2021328673A1 publication Critical patent/AU2021328673A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021328673A 2020-08-19 2021-08-18 CRF2 receptor agonists and their use in therapy Pending AU2021328673A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20315387.9 2020-08-19
EP20315387 2020-08-19
PCT/EP2021/072923 WO2022038179A1 (en) 2020-08-19 2021-08-18 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
AU2021328673A1 true AU2021328673A1 (en) 2023-03-30

Family

ID=72615799

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021328673A Pending AU2021328673A1 (en) 2020-08-19 2021-08-18 CRF2 receptor agonists and their use in therapy

Country Status (16)

Country Link
US (1) US20250243255A1 (enExample)
EP (2) EP4199946B1 (enExample)
JP (1) JP7832927B2 (enExample)
KR (1) KR20230051583A (enExample)
CN (1) CN116472053A (enExample)
AU (1) AU2021328673A1 (enExample)
CA (1) CA3192032A1 (enExample)
ES (1) ES2988026T3 (enExample)
HR (1) HRP20240906T1 (enExample)
HU (1) HUE066991T2 (enExample)
IL (1) IL300464A (enExample)
IS (1) IS3063B (enExample)
MX (1) MX2023002087A (enExample)
PL (1) PL4199946T3 (enExample)
WO (1) WO2022038179A1 (enExample)
ZA (1) ZA202301784B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
EP4234574A1 (en) * 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy
WO2025104264A1 (en) 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體２（ｃｒｆｒ２）促效劑
WO2025230248A1 (ko) * 2024-04-30 2025-11-06 한미약품 주식회사 Crf2 수용체 작용제와 그 아실화 결합체의 용도
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Also Published As

Publication number Publication date
KR20230051583A (ko) 2023-04-18
HRP20240906T1 (hr) 2024-10-11
EP4199946A1 (en) 2023-06-28
ZA202301784B (en) 2024-01-31
EP4435001A3 (en) 2024-10-09
WO2022038179A1 (en) 2022-02-24
PL4199946T3 (pl) 2024-08-19
IL300464A (en) 2023-04-01
HUE066991T2 (hu) 2024-09-28
MX2023002087A (es) 2023-03-23
JP2023541798A (ja) 2023-10-04
CN116472053A (zh) 2023-07-21
JP7832927B2 (ja) 2026-03-18
EP4199946C0 (en) 2024-06-05
IS3063B (is) 2025-06-15
US20250243255A1 (en) 2025-07-31
EP4435001A2 (en) 2024-09-25
ES2988026T3 (es) 2024-11-19
CA3192032A1 (en) 2022-02-24
EP4199946B1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
EP4199946B1 (en) Crf2 receptor agonists and their use in therapy
US9074014B2 (en) Analogues of glucose-dependent insulinotropic polypeptide
US9072703B2 (en) Glucose-dependent insulinotropic polypeptide analogues
JP7295871B2 (ja) 修飾された脂質化リラキシンｂ鎖ペプチドおよびその治療的使用
CN102532301B (zh) 一类新型的Exendin-4类似物及其制备方法
EP4482578B1 (en) Crf2 receptor agonists and their use in therapy
TW201940504A (zh) 經修飾之脂質化鬆弛素ｂ鏈胜肽及其治療用途
WO2024163535A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
HK40087027A (en) Crf2 receptor agonists and their use in therapy
HK40087027B (en) Crf2 receptor agonists and their use in therapy
JP2026071260A (ja) Ｃｒｆ２受容体アゴニスト及び治療におけるその使用
JPS60105697A (ja) ペプチド及びその製造方法並びに該ペプチドを含有する医薬
HK40095414A (en) Crf2 receptor agonists and their use in therapy
RU2804702C2 (ru) Модифицированные липидированные пептиды b-цепи релаксина и их терапевтическое применение
HK40112064A (zh) Crf2受体激动剂及其在治疗中的用途